Search

Overview

Clinical guidelines are our key activity supporting evidence-based clinical practice in rheumatology. All of these guidelines are published in our journal Rheumatology under an ‘open access’ licence.

Accreditation-logo-resize254x93

NICE accredits the process we use to produce our clinical guidelines. Accreditation is valid for five years from February 2018. For full details on accreditation visit their website.


Our guidelines grow out of the collaborative efforts of many members and non-members, specialists and generalists, patients and carers and all the MDT.

They are firmly embedded in practice – users lead the proposal, selection and development of all guideline topics – choosing areas where there is clinical uncertainty, where mortality or morbidity can be reduced and where NICE or other guide producers are unlikely to tread.

We neither seek nor accept industry funding for any of our guidelines. Their development is supported through our general finances.

Creating our guidelines is a major voluntary endeavour by members, patients and practitioners from primary care and other specialities. We are grateful to everyone for their strenuous efforts in producing them.

We want to hear your experiences of using the guidelines to help us spot patterns, create case studies and find solutions to problems.

How has care in your unit improved through implementation? What clinical issues have you resolved by using a guideline? Are you or your unit having problems implementing any part of the guidelines?

If there is anything else you would like to share with us about planning, creating, auditing or using the guidelines, please email guidelines@rheumatology.org.uk.

Current guidelines


Biological DMARD safety Guideline for the safe prescribing of biologics in adults with inflammatory arthritis.

Executive summary
Full guideline
Lupus Guideline for the management of adults with Systemic Lupus Erythematosus. 2017 NICE-accredited. Due for revision 2020

Executive summary
Full guideline
Audit tool
Podcast
Sjögren’s Syndrome Guideline for the management of adults with Primary Sjögren’s Syndrome. 2017 NICE-accredited. Due for revision 2020

Executive summary
Full guideline
Audit tool
Podcast
Gout Guideline for the management of gout. 2017 NICE-accredited. Due for revision 2020.

Executive summary
Full guideline
Audit tool
Podcast
DMARDs Guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. 2017 NICE-accredited. Due for revision 2020.

Executive summary
Full guideline
Audit tool
Podcast
Axial spondyloarthritis Guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. 2016 NICE-accredited. Due for revision 2019.

Executive summary
Full guideline
Audit tool
Podcast
Systemic sclerosis Guideline for the treatment of systemic sclerosis. 2016 NICE-accredited. Due for revision in 2019

Executive summary
Full guideline
Audit (See page 10 of the full GL for guidance on audit)
Podcast
Pregnancy and breastfeeding: Part 1 Guideline on prescribing drugs in pregnancy and breastfeeding Part 1: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. 2016 NICE-accredited. Due for revision in 2019.

Executive summary
Full guideline
Audit tool
Podcast
Pregnancy and breastfeeding: Part 2 Guideline on prescribing drugs in pregnancy and breastfeeding Part 2: analgesics and drugs used in rheumatology practice. 2016 NICE-accredited. Due for revision in 2019.

Executive summary
Full guideline
Audit tool
Podcast
PsA with biologics
Guideline for the treatment of psoriatic arthritis with biologics. 2013 NICE-accredited. In revision 2019.

Executive summary
Full guideline
PsA guidelines revision statement
Hot swollen joint
Guideline for management of hot swollen joint in adults.

The guideline for the management of the hot swollen joint was first published in 2006. Although there is not enough data to constitute a change in the guideline, there is sufficient new information to warrant an update within the next two years. Read the accompanying statement (issued March 2017) for more detail.

Renewed and accepted unchanged in 2012. Reviewed again in 2017. An update of the guideline will be due within the next two years. Due for revision in 2019.

Executive summary
Full guideline
Hot Joint guideline update
Polymyalgia rheumatica Guideline for the management of polymyalgia rheumatica.

SAGWG decided that the 2009 guideline, originally due for review 2015, remains current. It is substantially the same as the new 2015 EULAR/ACR guideline: Recommendations for the Management of Polymyalgia Rheumatica. Due for revision in 2019.

Executive summary
Full guideline
ANCA-associated vasculitis Guideline for the management of adults with ANCA-associated vasculitis. In revision 2019.

Executive summary
Full guideline and suggestions for audit

Guidelines in development


Adult patients with idiopathic inflammatory myopathy Management of adult patients with idiopathic inflammatory myopathy (myositis)
Paediatric patients with idiopathic inflammatory myopathy
Management of paediatric patients with idiopathic inflammatory myopathy (myositis)
Foot health in inflammatory arthritis Management of foot health in patients with inflammatory arthritis 

Guidelines under revision


Giant cell arteritis Guideline on the management of patients with giant cell arteritis.

Executive summary
Guideline
Audit Tool
Comments form
PsA with biologics
The treatment of PsA with biologics.

Executive summary
ANCA associated vasculitis
The management of adults with ANCA associated vasculitis.

Executive summary